Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertussis component immunogenicity study in Dutch infant DTP-IPV-Hib booster vaccination
NL-OMON22816Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Nov 2004
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of acellular pertussis vaccine, diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine and pneumococcal 7-valent conjugate vaccine in pertussis (5 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Pertussis immunogenicity comparison. Started Nov 2004; status: active, not recruiting.
02
Drugs
acellular pertussis vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccinepneumococcal 7-valent conjugate vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON22816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22816.